Annovis Bio Receives New NYSE Delisting Notice, Deepening Balance Sheet Crisis

What happened

Annovis Bio announced on October 30, 2026, that it received a continued listing standard notice from the NYSE on October 29, 2026, due to its average market capitalization over a 30-day period falling below $50 million while stockholders' equity also fell below $50 million. This follows the previous March 2025 notice and a June 2025 acceptance of a remediation plan, indicating that the company has failed to regain compliance within the 18-month cure period that ended in September 2026. The company remains a clinical-stage biotech with no revenue, $15.3 million in cash as of Q3 2025, a monthly burn around $2 million, and explicit going-concern language, leaving it highly dependent on dilutive financing to continue operations and fund the pivotal Phase 3 Alzheimer's trial. With the NYSE now moving toward potential delisting, the stock likely faces reduced institutional interest, limited liquidity, and even more punitive financing terms if the company is forced to raise capital on the OTC market. This development materially worsens the risk profile for equity holders, as the company must now urgently secure capital and address listing requirements while advancing a trial that is only about 25% complete.

Implication

Investors should expect heightened volatility and a potential slide toward the OTC market, which would shrink the investor base and make any future equity raises even more expensive and dilutive. The company's ability to continue as a going concern is now more closely tied to its ability to raise capital on acceptable terms, but with NYSE delisting looming, lenders and investors may demand deep discounts and heavy warrant coverage, further eroding per-share value. The pivotal Alzheimer's Phase 3 trial remains the only fundamental value driver, but with enrollment at only ~25% and cash runway limited to Q3 2026, the trial itself is at risk of delays or termination if funding is not secured. Insiders have been buying shares, but such purchases are small relative to the capital needed and do not offset the structural risks of delisting and insolvency; they may merely reflect a belief that the stock is deeply undervalued on long-term clinical potential. Given the new listing notice, the previous WAIT rating should be downgraded to a more cautious stance, with an emphasis on preserving capital and waiting for evidence of a credible financing solution or partnership before considering any new position.

Thesis delta

The prior thesis already emphasized going-concern and listing risk, but this new notice crystallizes that risk and shortens the timeline for action. The base case that Annovis would regain NYSE compliance through market cap recovery appears to have failed, shifting probability weight toward the bear scenario where delisting and punitive financing drive further value destruction. The thesis shifts from 'wait for de-risking funding or enrollment traction' to 'avoid or treat as a speculative trade only, as the equity may become increasingly impaired by delisting and capital structure deterioration.'